Get the Weekly Intelligence Brief — top committee picks every Sunday.
COR · NYSE · STOCK

Cencora (COR) Stock Analysis

Healthcare Updated October 10, 2026
$323.92
52W $244.82 – $377.54
56/100
$63.01B
24.0
0.58
AI Committee Verdict
Watch
56/100
Conviction: Contested · 50% agreement · 6 analysts
+4.5%
-11.7%
0.39:1
Contested

Is COR Bullish or Bearish?

Mixed. Innellis AI committee rates Cencora (COR) Watch with a composite score of 56/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +3.82 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -16.18 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 106.4% shows genuine earnings power backing the valuation — Value
  • EPS growing 38.4% YoY — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • Price-to-book of 40.2x prices in significant intangible value — Value
  • Debt-to-equity of 5.08 adds balance-sheet risk to the value case — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • High leverage (debt-to-equity 5.08) amplifies downside in a stress scenario — Risk
  • Current ratio of 0.90 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 59%
of 192 Healthcare peers
Value Analyst neutral
50 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 106.4% shows genuine earnings power backing the valuation
− Price-to-book of 40.2x prices in significant intangible value
Growth Analyst neutral
53 / 100 · High confidence
Moderate growth -- present but not remarkable
+ EPS growing 38.4% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
69 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst bearish
32 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 5.08) amplifies downside in a stress scenario
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.31 across 13 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 54.2 to 56.2.

Analyst-level changes:
  • News Analyst: +1 bullish signal(s).
  • Technical Analyst: stance neutral->bullish; score 58->69 (+10); +3 bullish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
68.8
Neutral
MACD Histogram
1.655
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$286.13
Resistance
$338.56
Bollinger %B
0.87
Inside Bands
Price vs Moving Averages
EMA 9
$316.22 Above
EMA 21
$315.37 Above
EMA 50
$314.25 Above
EMA 200
$311.41 Above

Fundamental Analysis

Valuation
55
Growth
53
Profitability
31
Financial Health
6
Cash Flow
70
Valuation
P/E Ratio 24.0×
P/B Ratio 20.50×
PEG Ratio 0.63
Dividend Yield 0.74%
52W High $377.54
52W Low $244.82
Quality & Growth
ROE 10306.0%
ROA 202.9%
Gross Margin 371.0%
Operating Margin 130.3%
Revenue Growth YoY —
Debt / Equity 3.84
AI Fundamental Assessment
P/E ratio of 24.0 (inexpensive relative to a 15-40x range); Price-to-book of 20.5x; PEG ratio of 0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 103.1%; Return on assets of 2.0%; Net margin of 0.8%; Gross margin of 3.7%; Current ratio of 0.93 (tight short-term liquidity); Debt-to-equity of 3.84; Free cash flow per share is positive (21.02); Most recent quarter beat estimates by 2.0%; EPS growth decelerating (+16.4% -> -5.7% QoQ); Average YoY EPS growth of 12.0%; Analyst estimates rising over recent quarters
Get the Full COR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime